The European Cooperation in Science and Technology (COST) provides an ideal framework to establish multi-disciplinary research networks. COST Action BM1203 (EU-ROS) represents a consortium of researchers from different disciplines who are dedicated to providing new insights and tools for better understanding redox biology and medicine and, in the long run, to finding new therapeutic strategies to target dysregulated redox processes in various diseases. This report highlights the major achievements of EU-ROS as well as research updates and new perspectives arising from its members. The EU-ROS consortium comprised more than 140 active members who worked together for four years on the topics briefly described below. The formation of reactive oxygen and nitrogen species (RONS) is an established hallmark of our aerobic environment and metabolism but RONS also act as messengers via redox regulation of essential cellular processes. The fact that many diseases have been found to be associated with oxidative stress established the theory of oxidative stress as a trigger of diseases that can be corrected by antioxidant therapy. However, while experimental studies support this thesis, clinical studies still generate controversial results, due to complex pathophysiology of oxidative stress in humans. For future improvement of antioxidant therapy and better understanding of redox-associated disease progression detailed knowledge on the sources and targets of RONS formation and discrimination of their detrimental or beneficial roles is required. In order to advance this important area of biology and medicine, highly synergistic approaches combining a variety of diverse and contrasting disciplines are needed.

No abstract

No abstract

We have previously described a series of monoclonal

Significance: Reactive Oxygen Species (ROS) may regulate signaling, ion channels, transcription factors, and biosynthetic processes. ROS-related diseases can be due to either a shortage or an excess of ROS. Recent Advances: Since the biological activity of ROS depends on not only concentration but also spatiotemporal distribution, real-time imaging of ROS, possibly in vivo, has become a need for scientists, with potential for clinical translation. New imaging techniques as well as new contrast agents in clinically established modalities were developed in the previous decade. Critical Issues: An ideal imaging technique should determine ROS changes with high spatio-temporal resolution, detect physiologically relevant variations in ROS concentration, and provide specificity toward different redox couples. Furthermore, for in vivo applications, bioavailability of sensors, tissue penetration, and a high signal-to-noise ratio are additional requirements to be satisfied. Future Directions: None of the presented techniques fulfill all requirements for clinical translation. The obvious way forward is to incorporate anatomical and functional imaging into a common hybrid-imaging platform. Antioxid. Redox Signal. 24, 939–958.

In this study, we have compared the generation of superoxide radical in rat hippocampal and striatal slices in the presence of specific mitochondrial electron transport chain (ETC) inhibitors (complexes I and III) under control and depolarization conditions [incubation in artificial cerebrospinal fluid (ACSF) or depolarizing ACSF (dACSF), respectively]. Superoxide radical generation was increased in both ACSF- and dACSF-incubated hippocampal and striatal slices when rotenone and antimycin A were added to the incubation medium. The increase in superoxide radical was dependent on the concentration of ETC inhibitors under control, but not depolarization conditions. Rotenone was found to be more effective than antimycin A in producing superoxide radical from hippocampal and striatal slices. Our results also showed that hippocampal slices were more sensitive to ETC inhibitors compared with striatal slices. Thus, different regions of the brain seem to differ in their capacity to generate free radicals and vulnerability to oxidative stress conditions. This difference should be considered in developing therapeutic modalities against oxidative stress-related disorders and neurodegeneration.

No abstract

No abstract